Compare Ascendis Pharma A/S (ASND) vs Old Dominion Freight Line Inc (ODFL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Old Dominion Freight Line Inc — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Old Dominion Freight Line Inc trades at $227.74 (market cap $47.34B). The key difference: Old Dominion Freight Line Inc is far larger — about 2.7× Ascendis Pharma A/S's market cap, and Old Dominion Freight Line Inc pays a 0.51% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | ODFL | |
|---|---|---|
Market Cap | $17.74B | $47.34B |
Sector | Health | Industrials |
52-Week High | $277.18 | $248.73 |
52-Week Low | $163.32 | $126.29 |
Enterprise Value | $18.11B | $47.09B |
Dividend Yield | — | 0.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
ODFL trades at $227.63, up 0.79% today, near its consensus price target of $231.29. The stock shows bullish technical signals with strong moving averages, though RSI indicates mild overbought conditions. Fundamentally, ODFL maintains high profitability with an 18.46% net margin and 23.33% ROE, but valuation ratios like P/E of 47.52 are elevated. Recent earnings beats and a solid balance sheet with minimal debt support its quality, while news highlights mixed sentiment amid freight market recovery and competitive pressures from Amazon's LTL expansion.
Outlook: ODFL offers a high-quality play on freight recovery with robust fundamentals, but rich valuation and near-term headwinds warrant caution. Upside depends on Q2 2026 earnings meeting the $1.51 EPS estimate. Risks include economic sensitivity and rising competition. Analyst consensus is mixed with 33% buy ratings, suggesting patience for better entry points may be prudent.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Old Dominion Freight Line Inc
Old Dominion Freight Line is the fourth-largest less-than-truckload carrier in the United States, with more than 240 service centers and 9,200-plus tractors. OD is by far one of the most disciplined and efficient providers in the trucking industry, and its profitability and capital returns stand head and shoulders above its peers. Strategic initiatives revolve around increasing network density through market share gains and maintaining industry-leading service via consistent infrastructure investment.
Read more on ODFL →
